

Monophasic OCs Said to Ease Menstrual Migraine

BY NANCY A. MELVILLE
Contributing Writer

SCOTTSDALE, ARIZ. — Fluctuating hormones are believed to be the key culprit behind menstrual migraines, so low-dose monophasic oral contraceptives are generally the best alternative to help such patients, Christine Lay, M.D., said at a symposium sponsored by the American Headache Society.

Physicians often turn to biphasic contraception instead of monophasic pills in the belief that varying the hormone dosage will help alleviate menstrual migraines, but the dosage schedule can in fact make the problem worse, said Dr. Lay, a neurologist with the Headache Institute at Roosevelt Hospital, New York.

Dr. Lay gave the example of Mircette, which contains 21 days of 0.15-mg desogestrel/0.02-mg ethinyl estradiol, followed by 2 days of placebo pills and 5 days of 0.01-mg ethinyl estradiol. She noted that numerous physicians prescribe Mircette thinking it might help patient's menstrually related migraines.

Instead, the method introduces another level of fluctuation of estrogen, and it is that fluctuation that is believed to trigger the migraines in the first place, said Dr. Lay. "It's not whether the estrogen is present or absent, but [it's] the change in estrogen and I find many patients don't do well on Mircette because of fluctuations in estrogen."

Even worse for menstrual migraines are triphasic pills, which cause greater fluctuation in hormone levels and often are high-dose pills, Dr. Lay said.

"The triphasic pills are the worst for migraine patients," she said. "Invariably, you will have a patient track her calendar and over a month's period of time she will report that within a day or two of switching to a new dose of pill, the woman will experience a migraine attack."

Migraine patients generally fare much better when using monophasic low-dose (20-mcg) birth control pills, which offer a more uniform hormone level, Dr. Lay said. She added that the estrogen patch is another effective way of providing a more steady level of estrogen.

Newer noncycling methods such as Seasonale (ethinyl estradiol and levonorgestrel) are also good alternatives for migraineurs, she said. "With a 91-day regimen, including 84 days of real pills and then the placebo pills, women skip perhaps three out of every four menstrual migraine attacks, because they're not having a menstrual cycle," Dr. Lay said in an interview.

Estrogen use in patients who suffered from migraines was frowned upon for many years, but the International Headache Society Task Force on Combined Oral Contraceptives and HRT determined more recently that it was safe for migraineurs, provided that there are no other risk factors for coronary heart disease or vascular disease.

In addition, the migraine should be without aura and patients should be given the lowest effective hormone dose.

In the ebb and flow of hormone levels,

it is the withdrawal of estrogen, specifically, that experts believe contributes to menstrual migraines. The withdrawal is believed not only to affect trigeminal pain pathways and have vasculature effects, but it may modulate neurotransmitters and magnesium, Dr. Lay said at the meeting.

The release of prostaglandin also plays a role in migraines, sensitizing peripheral nociceptors to pain and mediating hyperalgesia, and prostaglandin is known to increase during migraine attacks.

A key approach to treatment is having patients maintain a diary in which they track their menses and headache days, Dr. Lay said. The journal can help guide treatment options and determine the role of oral contraceptive use.

Since menstrual migraines can occur in young, otherwise healthy women, Dr. Lay strongly recommended using caution in approaching contraceptive issues.

"This is a critical time to discuss with patients pregnancy planning and med-

ication contraindications in pregnancy because, invariably, some of these patients could wind up getting pregnant" unintentionally.

"Physicians may have the patient go off the pill in order to observe the migraine pattern over time. However, the migraine pattern may not improve for at least 3-6 months. In such cases, it's essential to talk about pregnancy issues if the patient is on the pill for contraceptive purposes," she said. ■



*Zolpidem tartrate worldwide.

AMBIEN is the #1 prescribed sleep agent in the US²

AMBIEN is indicated for the short-term treatment of insomnia. In elderly or debilitated patients, or patients with hepatic dysfunction, treatment should be initiated with a 5-mg dose and patients closely monitored. Due to its rapid onset of action, patients should take AMBIEN right before going to bed and when ready for sleep. Patients should not take AMBIEN unless they are prepared to get a full night's sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN or any other sleep medication. During short-term treatment with AMBIEN, the most commonly observed adverse effects in controlled clinical trials were drowsiness (2%), dizziness (1%), and diarrhea (1%). Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN or any other hypnotic. AMBIEN is classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are taken for more than 2 to 3 weeks. Prescriptions for AMBIEN should not exceed a 1-month supply.

Please see brief summary of prescribing information on back.

sanofi aventis

Sanofi-Synthelabo Inc., a member of the sanofi-aventis Group

©2005 Sanofi-Synthelabo Inc.
57-050003

Visit our Web site at www.ambien.com

AMBIEN[®]
(ZOLPIDEM TARTRATE) [Ⓒ]
5-MG & 10-MG TABLETS

Restful nights, refreshed awakenings